Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy (CLARITY)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03221075|
Recruitment Status : Recruiting
First Posted : July 18, 2017
Last Update Posted : October 30, 2018
|Condition or disease||Intervention/treatment|
|Invasive Aspergillosis||Other: Registry|
For mold-active azoles (e.g. isavuconazole, itraconazole, posaconazole and voriconazole), cross-resistance of Aspergillus spp. is an increasingly recognized problem. The study aims to determine the efficacy of antifungal therapy in patients with documented azole-resistant IA. On the basis of this study, it will be possible to assess the clinical implications of IA caused by azole-resistant versus azole-susceptible Aspergillus spp.
The investigators aim at collecting at least 55 azole-resistant and 130 azole-susceptible cases. Cases diagnosed with an IA by culture from January 1st, 2016 onwards with an underlying hematological malignancy are eligible for inclusion. Culture of azole-resistant cases must be provided for confirmation of the species, sequencing for azole-resistance mutations and determination of MIC using the EUCAST reference method. Isolates obtained from patients with presumed azole-susceptible disease will be analyzed to confirm the wild type phenotype.
Eligible azole-resistant and azole-susceptible IA cases will be documented using the web-based case report form. If there is ≥1 resistant isolate, the patient fulfills the definition of a resistant case. Patient level data will be recorded at the respective study centres in a continuous fashion. Data items to be documented will include: demographic data; type and status of underlying conditions; concurrent immunosuppressive treatment; diagnostic measures (clinical presentation, radiology, microbiology, pathology, organ involvement); medical and surgical treatment (including prior exposure to antifungals); response to treatment (clinical and radiological) at day 14, 42, 84; overall survival at day 14, 42, 84 and at last contact; and cause of death (if applicable).
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||220 participants|
|Target Follow-Up Duration:||4 Years|
|Official Title:||CLARITY - Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy|
|Actual Study Start Date :||March 1, 2017|
|Estimated Primary Completion Date :||June 1, 2020|
|Estimated Study Completion Date :||July 1, 2020|
There is no intervention.
- Treatment response to antifungal therapy in patients with an invasive Aspergillosis caused by an azole resistant pathogen. [ Time Frame: Change from diagnosis at day 14, 28, 42 and 84 and throughout study completion ]Analysis of efficacy of antifungal therapy of azole-resistant and azole-susceptible invasive Aspergillosis. Patient receive either complete response, partial response, stable disease, progression of the disease. Treatment response will be assessed by treating physicians. Response will be compared between the two groups.
- Overall survival [ Time Frame: 4 years ]Final outcome will be compared between the two groups in consideration of the type and state of underlying diseases and risk factors.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03221075
|Contact: Dorothee Arenz, Dr.||+49 221 478 email@example.com|
|Contact: Susann Bloßfeld||+49 221 478 firstname.lastname@example.org|
|University Hospital of Cologne||Recruiting|
|Cologne, NRW, Germany, 50931|
|Contact: Oliver A. Cornely, Prof.|
|Radboud University Nijmegen Medical Center||Recruiting|
|Nijmegen, Netherlands, 6500|
|Contact: Paul E. Verweij, Prof.|
|Principal Investigator:||Oliver A. Cornely, Prof.||University Hospital of Cologne, Germany|
|Principal Investigator:||Paul E. Verweij, Prof.||Radboud University Nijmegen Medical Center, The Netherlands|